Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial

Molecular Psychiatry

Volumn 22, Issue 1, 2017, Pages 76-81

  Dakwar, E ^a   Hart, C L ^a,b   Levin, F R ^a   Nunes, E V ^a   Foltin, R W ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; KETAMINE; MIDAZOLAM; CENTRAL STIMULANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; BEHAVIOR CHANGE; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DELAY DISCOUNTING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SELF ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; MALE; MONEY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REWARD; ANTAGONISTS AND INHIBITORS; ASSOCIATION; COCAINE-RELATED DISORDERS; CRAVING; CROSSOVER PROCEDURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MOTIVATION;

ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; CRAVING; CROSS-OVER STUDIES; CUES; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; MOTIVATION; RECEPTORS, N-METHYL-D-ASPARTATE; SELF ADMINISTRATION;

EID: 84964329328     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.39     Document Type: Article

References (39)

1. Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell 2015; 162: 712-725.
2. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008; 33: 166-180.
3. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159: 1642-1652.
4. Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry 2014; 76: 40-46.
5. Popik P, Wrobel M, Rygla R, Bisaga A, Bespakov AY. Effect of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforces in mice. Behav Pharmacol 2003; 14: 237-244.
6. Collins ED, Ward AS, McDowell DM, Foltin RW, Fischman MW. The effects of memantine on the subjective, reinforcing, and cardiovascular effects of cocaine in human. Behav Pharmacol 1998; 9: 587-598.
7. Price KL, McRae-Clark AL, Saladin ME, Maria MM, DeSantis SM, Back SE et al. D-cycloserine and cocaine cue reactivity: preliminary findings. Am J Drug Alcohol Abuse 2009; 35: 434-438.
8. Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010; 111: 97-104.
9. Berglind WJ, See RE, Fuchs RA, Ghee SM, Whitfield TW Jr, Miller SW et al. A BDNF infusion into the medial prefrontal cortex suppresses cocaine seeking in rats. Eur J Neurosci 2007; 26: 757.
10. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008; 33: 761-768.
11. Stoops WW, Rush CR. Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des 2013; 19: 7026-7035.
12. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008; 96: 1-15.
13. Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis 2015; 6: 97-114.
14. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014; 17: 331-336.
15. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK et al. BDNF Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2010; 71: 996-1005.
16. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA et al. Increased anterior cingulate cortical activity in response to fearful faces: a neuro-physiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009; 65: 289-295.
17. Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PloS One 2012; 7: e44799.
18. First MB, Williams JBL, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV-TR Axis I Disorders Clinical Trials Version (SCID-CT), Biometrics Research, New York State Psychiatric Institute: New York, 2007.
19. William JB. A structured interview guide for the Hamilton Depression Scale. Arch Gen Psychiatry 1988; 45: 742-747.
20. Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986; 174: 727-735.
21. Foltin RW, Fischman MW, Nestadt G, Stromberger H, Cornell EE, Pearlson GD. Demonstration of naturalistic methods for cocaine smoking by human volunteers. Drug Alcohol Depend 1990; 26: 145-154.
22. Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007; 192: 253-260.
23. Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend 2014; 136: 153-157.
24. Stahl S. Stahl's Essential Psvchopharmacoloav: Neuroscientific Basis and Clinical Applications. Cambridge University Press: New York, NY, USA, 2008.
25. Sklar GS, Zukin SR, Reilly TA. Adverse reactions to ketamine anesthesia: abolition by psychological technique. Anesthesia 1981; 36: 183-187.
26. Bremner JJ, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al. Measurement of dissociative states with the Clinician Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11: 125-136.
27. SAS Inc. SAS. Cary, NC. 2003.
28. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment 2006; 13: 27-45.
29. Tang YY, Posner MI, Rothbart MK, Volkow ND. Circuitry of self-control and its role in reducing addiction. Trends Cogn Sci (e-pub ahead of print 13 July 2015).
30. Belujon P, Jakobowski NL, Dollish HK, Grace AA. Withdrawal from acute amphetamine induces an amygdala-driven attenuation of dopamine neuron activity: reversal by ketamine. Neuropsychopharmacology 2015; 41: 619-627.
31. Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P. mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res 2013; 247: 9-16.
32. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 20: 959-964.
33. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997; 29: 165-183.
34. Ramo DE, Grov C, Delucchi K, Kelly BC, Parsons JT. Typology of club drug use among young adults recruited using time-space sampling. Drug Alcohol Depend 2010; 107: 119-127.
35. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2015; 76: 247-252.
36. Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009; 105: S14-S25.
37. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010; 11: 642-651.
38. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 2014; 54: 119-139.
39. Larimer ME, Palmer RS, Marlatt GA. Relapse prevention. An overview of Marlatt's cognitive-behavioral model. Alcohol Res Health 1999; 23: 151-160.